The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Obiltoxaximab SFL

100 milligram(s)/millilitre Concentrate for solution for infusion

SFL Regulatory Services GmbHEU/1/20/1485/001

Main Information

Trade NameObiltoxaximab SFL
Active SubstancesObiltoxaximab
Strength100 milligram(s)/millilitre
Dosage FormConcentrate for solution for infusion
Licence HolderSFL Regulatory Services GmbH
Licence NumberEU/1/20/1485/001

Group Information

ATC CodeJ06BB22 obiltoxaximab

Status

Authorised/WithdrawnAuthorised
Licence Issued18/11/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back